NCT05110846View on ClinicalTrials.gov

A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus

PHASE2UnknownINTERVENTIONAL
Enrollment

96

Participants

Timeline

Start Date

February 22, 2022

Primary Completion Date

February 28, 2023

Study Completion Date

March 31, 2023

Conditions
ObesityType2 Diabetes
Interventions
DRUG

Placebo

Placebo

DRUG

CT-868

CT-868

Trial Locations (6)

90057

Carmot Clinical Center US01, Los Angeles

Unknown

Carmot Clinical Center MX04, Guadalajara

Carmot Clinical Center MX01, Monterrey

Carmot Clinical Center MX02, Monterrey

Carmot Clinical Center MX05, Mérida

Carmot Clinical Center MX03, Mexico City

Sponsors
All Listed Sponsors
lead

Carmot Therapeutics, Inc.

INDUSTRY

NCT05110846 - A Study of CT-868 in Overweight and Obese Participants With Type 2 Diabetes Mellitus | Biotech Hunter | Biotech Hunter